Based on our study, therapies targeting MYOF combined with ramucirumab, a new anti-VEGFR therapy, might provide an efficient alternative approach for metastatic CCRCC to increase overall and disease-specific survival in patients. The gene discussed is MYOF; the disease is nonpapillary renal cell carcinoma.